GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » Equity-to-Asset

Misonix (Misonix) Equity-to-Asset : 0.68 (As of Jun. 2021)


View and export this data going back to 2019. Start your Free Trial

What is Misonix Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Misonix's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $135.20 Mil. Misonix's Total Assets for the quarter that ended in Jun. 2021 was $198.86 Mil. Therefore, Misonix's Equity to Asset Ratio for the quarter that ended in Jun. 2021 was 0.68.

The historical rank and industry rank for Misonix's Equity-to-Asset or its related term are showing as below:

MSON' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.58   Med: 0.73   Max: 0.9
Current: 0.68

During the past 13 years, the highest Equity to Asset Ratio of Misonix was 0.90. The lowest was -1.58. And the median was 0.73.

MSON's Equity-to-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.65 vs MSON: 0.68

Misonix Equity-to-Asset Historical Data

The historical data trend for Misonix's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix Equity-to-Asset Chart

Misonix Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.84 0.73 0.72 0.68

Misonix Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.71 0.72 0.70 0.68

Competitive Comparison of Misonix's Equity-to-Asset

For the Medical Devices subindustry, Misonix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Misonix's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Misonix's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Misonix's Equity-to-Asset falls into.



Misonix Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Misonix's Equity to Asset Ratio for the fiscal year that ended in Jun. 2021 is calculated as

Equity to Asset (A: Jun. 2021 )=Total Stockholders Equity/Total Assets
=135.2/198.86
=0.68

Misonix's Equity to Asset Ratio for the quarter that ended in Jun. 2021 is calculated as

Equity to Asset (Q: Jun. 2021 )=Total Stockholders Equity/Total Assets
=135.2/198.86
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Misonix  (NAS:MSON) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Misonix Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Misonix's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Misonix (Misonix) Business Description

Traded in Other Exchanges
N/A
Address
1938 New Highway, Farmingdale, NY, USA, 11735
Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.
Executives
Paul A Laviolette director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz officer: Chief Operating Officer 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer officer: Chief Financial Officer 3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe director C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub officer: Sr. VP Wound 8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis director, officer: CEO 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker officer: SVP Sales - Surgical 4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley officer: President C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby director C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc 10 percent owner 2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p. 10 percent owner C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p. 10 percent owner 3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104